Scarica l'app Stockscreener
22.24
2.49%
0.54
Precedente Chiudi:
$21.70
Aprire:
$21.99
Volume 24 ore:
544.56K
Relative Volume:
2.35
Capitalizzazione di mercato:
$1.53B
Reddito:
-
Utile/perdita netta:
$-48.26M
Rapporto P/E:
-28.16
EPS:
-0.7899
Flusso di cassa netto:
$-45.04M
1 W Prestazione:
+7.65%
1M Prestazione:
+2.58%
6M Prestazione:
+74.84%
1 anno Prestazione:
+87.84%
Intervallo 1D:
$21.30
$23.03
Intervallo di 1 settimana:
$19.52
$23.03
Portata 52W:
$11.32
$25.94
Gh Research Plc Stock (GHRS) Company Profile
Compare GHRS vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
22.24 | 1.53B | 0 | -48.26M | -45.04M | -0.7899 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-13 | Iniziato | Needham | Buy |
| 2025-06-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-03-13 | Iniziato | Guggenheim | Buy |
| 2025-03-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-02-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-08-16 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-16 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Gh Research Plc Borsa (GHRS) Ultime notizie
What GH Research (GHRS)'s Phase 2a Postpartum Depression Breakthrough Means For Shareholders - simplywall.st
GH Research PLC (GHRS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GH Research PLC (GHRS) Valuation: PE, PB & Fair Value Analysis - TradingKey
GH Research PLC (GHRS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
GH Research PLC (GHRS) Institutional Confidence - TradingKey
GH Research PLC (GHRS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
GH Research PLC (GHRS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GH Research PLC (GHRS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
GH Research PLC (GHRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GH Research PLC (GHRS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
(GHRS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
GH Research (GHRS) Bounces 2.23% as Shares Test Key Resistance at $22.18Exhaustion Gap - newsline.com
GHRS Q1 2026 Earnings: Clinical-Stage Biotech Reports Narrower-Than-Expected Operating Loss Amid Pipeline ProgressEarnings Power Value - newsline.com
Do GH Research’s (GHRS) Phase 2a Postpartum Data Subtly Reframe Its Broader Depression Strategy? - simplywall.st
GH Research PLC (GHRS) Gains Ground After Testing Support, Resistance in FocusAscending Triangle - newsline.com
GH Research Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues Clinical DevelopmentReturn On Assets - newsline.com
GHRS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
H.C. Wainwright Maintains Buy Rating on GH Research (GHRS) - Insider Monkey
GH RESEARCH PLC (GHRS) Stock Chart - ChartMill
GH Research earnings ahead: Can cash sustain Phase 3 ambitions? - Investing.com
5 Stocks That Have the Potential to Rise 1000% - Insider Monkey
(GHRS) Risk Channels and Responsive Allocation - Stock Traders Daily
GH Research Publishes Positive Phase 2a Postpartum Depression Data and Secures CINP 2026 Slots for GH001 - TipRanks
GH Research (NASDAQ: GHRS) highlights Phase 2 GH001 results in postpartum and treatment-resistant depression - Stock Titan
GH Research publishes phase 2a postpartum depression results By Investing.com - Investing.com Australia
GH Research publishes phase 2a postpartum depression results - Investing.com
GH Research Announces Publication of Phase 2a Postpartum Depression Results - Yahoo Finance UK
GHRS Q1 2026 Earnings: Miss on EPS as Clinical-Stage Biotech Deepens R&D InvestmentFinancial Health Score - newsline.com
Psychedelic drug stocks are surging after Trump's order to fast-track development for medical use - AOL.com
GH Research (GHRS) Surges Over 7%: Testing Key Resistance at $25.19Chandelier Stop - newsline.com
GH Research (GHRS) Surges 7.19% as Breakout Above $25.19 Resistance Becomes Key TestOvernight Profile - The Legal Advocate
Certain Options of GH Research PLC are subject to a Lock-Up Agreement Ending on 30-MAY-2026. - marketscreener.com
62,029,395 Common Stock of GH Research PLC are subject to a Lock-Up Agreement Ending on 30-MAY-2026. - marketscreener.com
GHRS Q1 2026 Earnings: Wider-than-Expected Loss Underscores Clinical-Stage ChallengesEarnings Miss Streak - newsline.com
GH Research (GHRS) Jumps 3.35% as Shares Approach Key Resistance at $24.0Insider Selling Alerts - The Legal Advocate
(GHRS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
GH Research Stock Moves as Market Eyes Data in Holiday Week - Bez Kabli
Assessing GH Research (GHRS) Valuation After Positive Phase 2b Data For GH001 In Treatment Resistant Depression - Sahm
GH Research to Present New GH001 Phase 2b Data in Treatment-Resistant Depression at ASCP 2026 - TipRanks
GH Research (NASDAQ: GHRS) highlights Phase 2b GH001 gains in treatment-resistant depression - Stock Titan
[EFFECT] GH Research PLC SEC Filing - Stock Titan
GH Research: Rapid Onset And Short Action Change The Treatment Paradigm (NASDAQ:GHRS) - Seeking Alpha
GHRS Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
H.C. Wainwright lowers GH Research stock price target on dilution By Investing.com - Investing.com South Africa
H.C. Wainwright lowers GH Research stock price target on dilution - Investing.com
Lynx1 and Weston Nichols report 17.4% stake in GH Research (NASDAQ: GHRS) - Stock Titan
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Phase 2b JAMA Data and New Financing Tools Could Be A Game Changer For GH Research (GHRS) - simplywall.st
Assessing GH Research (GHRS) Valuation After Key Phase 2b Results And Phase 3 Trial Plans - Yahoo Finance
GHRS SEC FilingsGh Research Plc 10-K, 10-Q, 8-K Forms - Stock Titan
GHRS Maintained by Cantor Fitzgerald -- Price Target Raised to $35 - GuruFocus
Gh Research Plc Azioni (GHRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):